debt_leverage_profile
0.46x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low sensitivity; ProPhase carries minimal long-term debt, so a 20bp rate move has negligible P&L impact (~<$200K annual interest expense change).
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Reagent and diagnostic consumable suppliers concentrated in China/Southeast Asia; semiconductor shortages affecting diagnostic device components are secondary chokepoint.
Inferred
Agent_Inference
international_expansion_readiness
Predominantly US-revenue company; minimal international exposure means sovereign currency devaluation risk is near-zero across top markets.
Inferred
Agent_Inference
geographic_footprint
~95%+ revenue is US-domestic (genomics, diagnostics, OTC); currency devaluation risk from international markets is negligible given near-absent foreign revenue.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Genomic sequencing reliance on Illumina platform likely exceeds 30% of lab input cost; Illumina is a non-substitutable short-term vendor creating high lock-in risk.
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption risk is moderate; diagnostic lab operations are partially on-premise, but bioinformatics/genomics data pipelines depend on cloud infrastructure.
Inferred
Agent_Inference
business_model_type_secondary
Secondary model is OTC consumer health products (Cold-EEZE brand); entirely physical retail distribution, immune to cloud infrastructure termination.
Inferred
Agent_Inference
switching_cost_profile
Illumina sequencing API/instrument ecosystem creates high switching costs; migrating to alternative platforms (PacBio, Oxford Nanopore) requires 12–24 months and capital outlay.
Inferred
Agent_Inference
howey_test_risk_index
Primary revenue (diagnostic testing services, genomics) fails Howey Test — no investment contract, no profit expectation from others' efforts; securities classification risk is negligible.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
HIPAA is primary compliance framework; CCPA exposure exists for genomic data of California residents; GDPR exposure minimal given near-zero EU operations.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; ProPhase holds no dominant market position in genomics or OTC health; faces competitive pressure rather than exerting pricing power.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (~80–90%); diagnostic testing is per-sample fee-for-service; OTC retail is unit-sale transactional; recurring contract revenue is a small minority.
Inferred
Agent_Inference
monetization_vector
Per-sample genomic sequencing fees and OTC retail unit sales; B2B diagnostic contracts provide limited recurring component; no meaningful SaaS or subscription monetization.
Inferred
Agent_Inference
pricing_architecture
Fee-for-service diagnostic pricing is vulnerable to payer reimbursement cuts and CMS rate changes; OTC pricing faces private-label competition; limited ability to raise prices unilaterally.
Inferred
Agent_Inference
pricing_power_rating
Weak-to-moderate; commodity diagnostic testing and OTC cold remedies face significant substitution pressure; pricing largely dictated by insurance reimbursement schedules and retail buyers.
Inferred
Agent_Inference
target_gross_margin_bracket
31.9% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
churn_vulnerability_index
No significant free-rider problem; diagnostic services require payment per test; OTC is retail purchase. Churn risk is high due to low switching costs for testing customers.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is largely headcount-linear in lab operations; scaling genomic throughput requires additional lab technicians and equipment; limited software-driven sublinear scaling.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is moderate-high; lab capacity expansion requires capex and labor; OTC growth leverages existing manufacturing contracts with low incremental headcount.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; ProPhase does not operate a franchise network.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics are challenging; diagnostic B2B sales require direct sales force; unit economics improve modestly with lab utilization but sales cost scales proportionally.
Inferred
Agent_Inference
network_effect_present
Minimal network effects; genomic database scale provides weak data network effect for research offerings but core diagnostic/OTC businesses have no meaningful network dynamics.
Inferred
Agent_Inference
asset_efficiency_ratio
-39.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate recession resistance; diagnostic testing (especially COVID/respiratory) has inelastic demand; OTC cold remedy is consumer staple; genomics elective testing is recession-sensitive.
Inferred
Agent_Inference
customer_segment_primary
B2B healthcare providers, hospitals, and employer testing programs for genomic/diagnostic services; customer concentration risk is elevated if top 5 clients exceed 30% of revenue.
Inferred
Agent_Inference
customer_segment_secondary
Retail consumers purchasing Cold-EEZE OTC products through mass-market retailers (CVS, Walgreens, Walmart); retailer concentration risk if any single chain represents >25% of OTC revenue.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
3.2% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0000868278
High
SEC-EDGAR
ticker
PRPH
High
SEC-EDGAR